Deficiência nutricional em bastão-do-imperador (Etlingera elatior (Jack) R. M. Smith): efeito na produção de matéria seca e índices biométricos Nutritional deficiency in torch ginger (Etlingera elatior (Jack) R. M. Smith): effect on dry matter production and biometrical index

Neste trabalho, objetivou-se avaliar os efeitos de omissões de nutrientes na produção de matéria seca e nos parâmetros de crescimento do bastão-do-imperador. O trabalho foi realizado em casa de vegetação da área experimental do Departamento de Ciência do Solo da Universidade Federal de Lavras (Lavras, MG), no período de janeiro de 2007 a janeiro de 2008. O delineamento experimental foi inteiramente casualizados com quatro repetições e oito tratamentos: Solução Hoagland & Arnon completa, soluções nutritivas com as omissões de N, de P, de K, de Ca, de Mg, de S e de B. Foram avaliadas a altura das plantas, diâmetro das hastes, número de hastes, número de folhas por hastes e volume da raiz. Posteriormente, as plantas foram divididas em folhas, hastes, rizoma e raiz para determinação da massa de matéria seca de cada parte. A omissão de nutrientes afetou os parâmetros de crescimento das plantas e a produção de matéria seca. Observou-se que o bastão-do-imperador mostrou-se mais exigente em B, K, N, P e S na fase inicial de crescimento do que em Ca e Mg. A redução da matéria seca total das plantas foi influenciada na seguinte ordem: B > K > N > P > S > Mg > Ca.<br>The objective of this work was to evaluate the effect of simple and multiple nutrient omissions on the dry matter production and growth parameters of torch ginger plants. The experiment was carried out under greenhouse conditions at the Soil Science Department of Federal University of Lavras (Lavras-MG). The experiment was started in January 2007 and lasted for 12 months, following a completely randomized design, with four replicates and eight treatments: Complete Hoagland & Arnon nutrient solution, and nutrient solutions without N, P, K, Ca, Mg, S, and B. Plant height, stem diameter, number of stems, number of leaves per stem, and volume of root were evaluated. Subsequently the plants were divided into leaf + pseudostem, rhizome, root and tillers for dry matter determination. The nutrient omissions affected the growth parameters and dry matter production. It was observed that torch ginger is more demanding in B, K, N, P and S at the initial phase of growth rather than in Ca and Mg. The reduction of the total dry matter weight of the plants was affected in the following order: B> K> N> P> S> Mg> Ca

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

© 2020 Elsevier Ltd. All rights reserved.Background: Hereditary transthyretin-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyretin (TTR) gene. We assessed the safety and efficacy of long-term treatment with patisiran, an RNA interference therapeutic that inhibits TTR production, in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Methods: This multicentre, open-label extension (OLE) trial enrolled patients at 43 hospitals or clinical centres in 19 countries as of Sept 24, 2018. Patients were eligible if they had completed the phase 3 APOLLO or phase 2 OLE parent studies and tolerated the study drug. Eligible patients from APOLLO (patisiran and placebo groups) and the phase 2 OLE (patisiran group) studies enrolled in this global OLE trial and received patisiran 0·3 mg/kg by intravenous infusion every 3 weeks with plans to continue to do so for up to 5 years. Efficacy assessments included measures of polyneuropathy (modified Neuropathy Impairment Score +7 [mNIS+7]), quality of life, autonomic symptoms, nutritional status, disability, ambulation status, motor function, and cardiac stress, with analysis by study groups (APOLLO-placebo, APOLLO-patisiran, phase 2 OLE patisiran) based on allocation in the parent trial. The global OLE is ongoing with no new enrolment, and current findings are based on the interim analysis of the patients who had completed 12-month efficacy assessments as of the data cutoff. Safety analyses included all patients who received one or more dose of patisiran up to the data cutoff. This study is registered with ClinicalTrials.gov, NCT02510261. Findings: Between July 13, 2015, and Aug 21, 2017, of 212 eligible patients, 211 were enrolled: 137 patients from the APOLLO-patisiran group, 49 from the APOLLO-placebo group, and 25 from the phase 2 OLE patisiran group. At the data cutoff on Sept 24, 2018, 126 (92%) of 137 patients from the APOLLO-patisiran group, 38 (78%) of 49 from the APOLLO-placebo group, and 25 (100%) of 25 from the phase 2 OLE patisiran group had completed 12-month assessments. At 12 months, improvements in mNIS+7 with patisiran were sustained from parent study baseline with treatment in the global OLE (APOLLO-patisiran mean change -4·0, 95 % CI -7·7 to -0·3; phase 2 OLE patisiran -4·7, -11·9 to 2·4). Mean mNIS+7 score improved from global OLE enrolment in the APOLLO-placebo group (mean change from global OLE enrolment -1·4, 95% CI -6·2 to 3·5). Overall, 204 (97%) of 211 patients reported adverse events, 82 (39%) reported serious adverse events, and there were 23 (11%) deaths. Serious adverse events were more frequent in the APOLLO-placebo group (28 [57%] of 49) than in the APOLLO-patisiran (48 [35%] of 137) or phase 2 OLE patisiran (six [24%] of 25) groups. The most common treatment-related adverse event was mild or moderate infusion-related reactions. The frequency of deaths in the global OLE was higher in the APOLLO-placebo group (13 [27%] of 49), who had a higher disease burden than the APOLLO-patisiran (ten [7%] of 137) and phase 2 OLE patisiran (0 of 25) groups. Interpretation: In this interim 12-month analysis of the ongoing global OLE study, patisiran appeared to maintain efficacy with an acceptable safety profile in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Continued long-term follow-up will be important for the overall assessment of safety and efficacy with patisiran.info:eu-repo/semantics/publishedVersio